O	0	10	Randomized
O	11	15	sham
O	15	16	-
O	16	26	controlled
O	27	32	pilot
O	33	38	trial
O	39	41	of
O	42	48	weekly
B-intervention	49	56	electro
I-intervention	56	57	-
I-intervention	57	68	acupuncture
O	69	72	for
O	73	76	the
O	77	87	prevention
O	88	90	of
B-condition	91	97	taxane
I-condition	97	98	-
I-condition	98	105	induced
I-condition	106	116	peripheral
I-condition	117	127	neuropathy
O	128	130	in
O	131	136	women
O	137	141	with
O	142	147	early
O	148	153	stage
O	154	160	breast
O	161	167	cancer
O	167	168	.

O	169	171	To
O	172	183	investigate
O	184	187	the
O	188	194	effect
O	195	197	of
O	198	205	electro
O	205	206	-
O	206	217	acupuncture
O	218	219	(
O	219	221	EA
O	221	222	)
O	223	225	as
O	226	227	a
O	228	231	non
O	231	232	-
O	232	247	pharmacological
O	248	260	intervention
O	261	263	to
O	264	271	prevent
O	272	274	or
O	275	281	reduce
O	282	294	chemotherapy
O	294	295	-
O	295	302	induced
O	303	313	peripheral
O	314	324	neuropathy
O	325	326	(
O	326	330	CIPN
O	330	331	)
O	332	334	in
O	335	341	breast
O	342	348	cancer
O	349	357	patients
O	358	368	undergoing
O	369	381	chemotherapy
O	382	384	of
O	385	391	taxane
O	391	392	.

B-eligibility	393	398	Women
I-eligibility	399	403	with
I-eligibility	404	409	stage
I-eligibility	410	411	I
I-eligibility	411	412	-
I-eligibility	412	415	III
I-eligibility	416	422	breast
I-eligibility	423	429	cancer
I-eligibility	430	439	scheduled
I-eligibility	440	442	to
I-eligibility	443	450	receive
I-eligibility	451	457	taxane
I-eligibility	458	465	therapy
O	466	470	were
O	471	481	randomized
O	482	484	to
O	485	492	receive
O	493	494	a
B-control	495	507	standardized
I-control	508	516	protocol
I-control	517	519	of
I-control	520	522	12
I-control	523	527	true
O	528	530	or
O	531	535	sham
O	536	538	EA
O	539	540	(
O	540	543	SEA
O	543	544	)
O	545	551	weekly
O	552	562	treatments
O	563	573	concurrent
O	574	578	with
O	579	585	taxane
O	586	595	treatment
O	595	596	.

O	597	605	Subjects
O	606	615	completed
O	616	619	the
O	620	625	Brief
O	626	630	Pain
O	631	640	Inventory
O	640	641	-
O	641	646	Short
O	647	651	Form
O	652	653	(
O	653	656	BPI
O	656	657	-
O	657	659	SF
O	659	660	)
O	660	661	,
O	662	672	Functional
O	673	683	Assessment
O	684	686	of
O	687	693	Cancer
O	694	701	Therapy
O	701	702	-
O	702	708	Taxane
O	709	722	neurotoxicity
O	723	731	subscale
O	732	733	(
O	733	737	FACT
O	737	738	-
O	738	741	NTX
O	741	742	)
O	742	743	,
O	744	747	and
O	748	753	other
O	754	765	assessments
O	766	768	at
O	769	777	baseline
O	778	781	and
O	782	787	weeks
O	788	789	6
O	789	790	,
O	791	793	12
O	793	794	,
O	795	798	and
O	799	801	16
O	801	802	.

O	803	804	A
O	805	810	total
O	811	813	of
B-total-participants	814	817	180
O	818	826	subjects
O	827	831	were
O	832	840	screened
O	840	841	,
B-total-participants	842	844	63
O	845	853	enrolled
O	854	857	and
B-total-participants	858	860	48
O	861	870	completed
O	871	875	week
O	876	878	16
O	879	890	assessments
O	890	891	.

B-age	892	896	Mean
I-age	897	900	age
I-age	901	904	was
I-age	905	907	50
O	908	912	with
O	913	915	25
O	916	917	%
B-ethinicity	918	923	white
O	923	924	,
O	925	927	25
O	928	929	%
B-ethinicity	930	935	black
O	935	936	,
O	937	940	and
O	941	943	43
O	944	945	%
B-ethinicity	946	954	Hispanic
O	954	955	;
O	956	958	52
O	959	960	%
O	961	964	had
O	965	967	no
O	968	973	prior
O	974	986	chemotherapy
O	986	987	.

B-outcome	988	990	At
I-outcome	991	995	week
I-outcome	996	998	12
O	998	999	,
O	1000	1004	both
O	1005	1011	groups
O	1012	1020	reported
O	1021	1023	an
O	1024	1032	increase
O	1033	1035	in
B-outcome	1036	1040	mean
I-outcome	1041	1044	BPI
I-outcome	1044	1045	-
I-outcome	1045	1047	SF
I-outcome	1048	1053	worst
I-outcome	1054	1058	pain
I-outcome	1059	1064	score
O	1064	1065	,
O	1066	1069	but
O	1070	1072	no
O	1073	1077	mean
O	1078	1089	differences
O	1090	1094	were
O	1095	1100	found
O	1101	1108	between
O	1109	1115	groups
O	1116	1117	(
O	1117	1120	SEA
B-iv-cont-mean	1121	1122	2
I-iv-cont-mean	1122	1123	.
I-iv-cont-mean	1123	1124	8
O	1125	1127	vs
O	1127	1128	.
O	1129	1131	EA
B-cv-cont-mean	1132	1133	2
I-cv-cont-mean	1133	1134	.
I-cv-cont-mean	1134	1135	6
O	1135	1136	,
O	1137	1138	P
O	1139	1140	=
O	1141	1142	.
O	1142	1144	86
O	1144	1145	)
O	1145	1146	.

O	1147	1149	By
B-outcome	1150	1154	week
I-outcome	1155	1157	16
O	1157	1158	,
O	1159	1162	the
O	1163	1166	SEA
O	1167	1172	group
O	1173	1181	returned
O	1182	1184	to
O	1185	1193	baseline
O	1193	1194	,
O	1195	1200	while
O	1201	1204	the
O	1205	1207	EA
O	1208	1213	group
O	1214	1223	continued
O	1224	1226	to
O	1227	1233	worsen
O	1234	1235	(
O	1235	1238	SEA
B-iv-cont-mean	1239	1240	1
I-iv-cont-mean	1240	1241	.
I-iv-cont-mean	1241	1242	7
O	1243	1245	vs
O	1245	1246	.
O	1247	1249	EA
B-cv-cont-mean	1250	1251	3
I-cv-cont-mean	1251	1252	.
I-cv-cont-mean	1252	1253	4
O	1253	1254	,
O	1255	1256	P
O	1257	1258	=
O	1259	1260	.
O	1260	1262	03
O	1262	1263	)
O	1263	1264	.

O	1265	1268	The
O	1269	1277	increase
O	1278	1280	in
B-outcome	1281	1284	BPI
I-outcome	1284	1285	-
I-outcome	1285	1287	SF
I-outcome	1288	1293	worst
I-outcome	1294	1298	pain
I-outcome	1299	1304	score
O	1305	1308	was
O	1309	1310	1
O	1310	1311	.
O	1311	1313	62
O	1314	1320	points
O	1321	1327	higher
O	1328	1330	in
O	1331	1334	the
O	1335	1337	EA
O	1338	1343	group
O	1344	1348	than
O	1349	1351	in
O	1352	1355	the
O	1356	1359	SEA
O	1360	1365	group
O	1366	1368	at
O	1369	1373	week
O	1374	1376	16
O	1377	1378	(
O	1378	1379	P
O	1380	1381	=
O	1382	1383	.
O	1383	1385	04
O	1385	1386	)
O	1386	1387	.

O	1388	1390	In
O	1391	1392	a
O	1393	1403	randomized
O	1403	1404	,
O	1405	1409	sham
O	1409	1410	-
O	1410	1420	controlled
O	1421	1426	trial
O	1427	1429	of
O	1430	1432	EA
O	1433	1436	for
O	1437	1447	prevention
O	1448	1450	of
O	1451	1457	taxane
O	1457	1458	-
O	1458	1465	induced
O	1466	1470	CIPN
O	1470	1471	,
O	1472	1477	there
O	1478	1482	were
O	1483	1485	no
O	1486	1497	differences
O	1498	1500	in
B-outcome	1501	1505	pain
I-outcome	1506	1508	or
I-outcome	1509	1519	neuropathy
O	1520	1527	between
O	1528	1534	groups
O	1535	1537	at
O	1538	1542	week
O	1543	1545	12
O	1545	1546	.

O	1547	1549	Of
O	1550	1557	concern
O	1557	1558	,
O	1559	1567	subjects
O	1568	1570	on
O	1571	1573	EA
O	1574	1577	had
O	1578	1579	a
O	1580	1586	slower
O	1587	1595	recovery
O	1596	1600	than
O	1601	1604	SEA
O	1605	1613	subjects
O	1613	1614	.

O	1615	1621	Future
O	1622	1629	studies
O	1630	1636	should
O	1637	1642	focus
O	1643	1645	on
O	1646	1648	EA
O	1649	1652	for
O	1653	1662	treatment
O	1663	1665	as
O	1666	1673	opposed
O	1674	1676	to
O	1677	1687	prevention
O	1688	1690	of
O	1691	1695	CIPN
O	1695	1696	.
